These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35029518)

  • 1. Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
    Schmulenson E; Zimmermann N; Mikus G; Joerger M; Jaehde U
    Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1407-1422. PubMed ID: 35029518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre.
    Moloney M; Faulkner D; Link E; Rischin D; Solomon B; Lim AM; Zalcberg JR; Jefford M; Michael M
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):865-876. PubMed ID: 30178115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
    Schneider JJ; Galettis P; Martin JH
    Br J Clin Pharmacol; 2021 Feb; 87(2):317-325. PubMed ID: 33386659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature.
    Fahmy A; Hopkins AM; Sorich MJ; Rowland A
    Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):803-821. PubMed ID: 34278936
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
    van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
    Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
    Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
    Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
    Wilhelm M; Mueller L; Miller MC; Link K; Holdenrieder S; Bertsch T; Kunzmann V; Stoetzer OJ; Suttmann I; Braess J; Birkmann J; Roessler M; Moritz B; Kraff S; Salamone SJ; Jaehde U
    Clin Colorectal Cancer; 2016 Dec; 15(4):381-388. PubMed ID: 27256667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How can we best monitor 5-FU administration to maximize benefit to risk ratio?
    Goirand F; Lemaitre F; Launay M; Tron C; Chatelut E; Boyer JC; Bardou M; Schmitt A
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1303-1313. PubMed ID: 30451549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology.
    Erku D; Schneider J; Scuffham P
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00862. PubMed ID: 34546005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of 5-fluorouracil.
    Lee JJ; Beumer JH; Chu E
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):447-64. PubMed ID: 27217046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics: the therapeutic drug monitoring of the future?
    Ensom MH; Chang TK; Patel P
    Clin Pharmacokinet; 2001; 40(11):783-802. PubMed ID: 11735602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
    Cardoso E; Guidi M; Blanchet B; Schneider MP; Decosterd LA; Buclin T; Csajka C; Widmer N
    Ther Drug Monit; 2020 Feb; 42(1):33-44. PubMed ID: 31479043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies.
    Papamichael K; Cheifetz AS
    Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1423-1431. PubMed ID: 34996330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework.
    Centanni M; Reijnhout N; Thijs A; Karlsson MO; Friberg LE
    Clin Pharmacokinet; 2024 Jun; 63(6):871-884. PubMed ID: 38842789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update.
    Kiang TK; Ensom MH
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):545-53. PubMed ID: 27021063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
    Levêque D; Becker G
    Expert Opin Drug Saf; 2019 Nov; 18(11):1009-1015. PubMed ID: 31478396
    [No Abstract]   [Full Text] [Related]  

  • 19. A high throughput immunoassay for the therapeutic drug monitoring of tegafur.
    Broto M; McCabe R; Galve R; Marco MP
    Analyst; 2017 Jun; 142(13):2404-2410. PubMed ID: 28555688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.
    Arshad U; Ploylearmsaeng SA; Karlsson MO; Doroshyenko O; Langer D; Schömig E; Kunze S; Güner SA; Skripnichenko R; Ullah S; Jaehde U; Fuhr U; Jetter A; Taubert M
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):711-722. PubMed ID: 32152679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.